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ORIGINAL ARTICLE
Background: Survivors of stage I lung cancer are at increased risk of 
subsequent malignancies. Specific data on risk of subsequent malig-
nancies are underreported in the literature. We studied the incidence 
of stage I lung cancer and the incidence of all second malignancies 
in survivors.
Methods: Data from the Surveillance, Epidemiology and End 
Results 9 database were analyzed to calculate the incidence of stage 
I lung cancer and subsequent malignancies from 1998 to 2007. The 
risk of subsequent malignancies is reported as a standardized inci-
dence ratio (observed incidence [O]/expected incidence [E]). 
Results: The incidence rate of stage I lung cancer increased slowly 
from 1988 (8, confidence interval [CI]: 7.6–8.4) to 2003 (9.2, CI: 
8.9–9.6) and more rapidly from 2003 to 2007 (11.2, CI: 10.8–11.7). 
The risk of developing a second lung cancer is highest in the first 
year with the O/E at 6.78 (CI: 6.29–7.31) and continues to be high at 
10 years (O/E 4.12; CI: 4.44–4.80). Laryngeal cancer has the highest 
incidence in the first year (O/E 9.78; CI: 7.51–12.51) and continues 
to be high at 10 years (O/E 3.55; CI: 1.77–6.34). For gastrointestinal 
cancers, there is increased risk of colon (O/E 1.33; CI: 1.22–1.44), 
esophagus (O/E 2.29; CI: 1.85–2.89), and stomach (O/E 1.43; CI: 
1.15–1.75) cancers. The increased risk of bladder cancer (O/E 1.83; 
CI: 1.65–2.03) remains high even at 10 years after the diagnosis of 
stage I lung cancer.
Conclusions: There is increasing incidence of stage I lung can-
cer. Survivors of stage I are at increased risk of certain second 
malignancies.
Key Words: Stage I lung cancer, Lung cancer survivorship, Second 
malignancies.
(J Thorac Oncol. 2012;7: 1252–1256)
In the past decade, the increased use of computed tomog-raphy (CT) scan in health care1 led to an increased num-
ber of patients diagnosed with asymptomatic early stage lung 
cancer. Most cancers diagnosed by CT screening are stage 
I2,3 where survival can approach almost 90%, as shown in 
the International Early Lung Cancer Action Program trial.3 
Recently, the National Cancer Institute sponsored National 
Lung Screening Trial of CT screening for lung cancer 
reported a survival benefit in the high-risk population stud-
ied.3–5 Widespread adoption of CT screening in clinical prac-
tice may lead to an increase in the number of early stage lung 
cancer patients identified, thereby leading to an increase in the 
number of long-term survivors.
There are several known risk factors for lung cancer: 
cigarette smoking,6 asbestos exposure,7 radon exposure,8 
and several genetic factors.9 In addition, life expectancy has 
increased, which may increase a person’s cumulative life-
time exposure to carcinogens, thus increasing their risk of 
developing malignancy. Survivors of lung cancer are sub-
sequently at higher risk for various second malignancies. 
Although there are few reports addressing the risk of second 
lung cancers in patients treated for early stage lung cancer, 
the incidence of all second malignancies in this population 
has not been reported in the literature. In a systematic review 
of studies published in Medline database from 1990 to 1997, 
Johnson10 reported that in patients treated successfully for 
lung cancer, there is an increased risk of a second lung can-
cer at 1% to 2% per year for non–small-cell lung cancer and 
2% to 10% per year for small-cell lung cancer persisting 
for 10 years after initial treatment. A subgroup analysis of 
patients who underwent surgical resection for stage I lung 
cancer in the intergroup trial examining the effectiveness of 
isotretinoin-A showed an incidence of second lung cancer 
of 15% at 5.9 years of follow-up.11 In a recent analysis com-
paring the incidence and outcome of second primary versus 
synchronous lung cancers in the Surveillance, Epidemiology 
and End results (SEER) database, Bhaskarla12 reported a 
cumulative incidence of second lung cancer of 1.5% for all 
lung cancer patients. Our objective is to identify the inci-
dence of all subsequent malignancies in survivors of stage 
I lung cancer. Incidence rates of second malignancies may 
become a useful target for screening studies and behavior 
modification strategies.
MATERIALS AND METHODS
SEER Database
Our study used data from the SEER 9 database. SEER 
is a cancer registry of the National Cancer Institute, which 
collects and reports statistics of cancer incidence and survival 
from nine population-based central cancer registries that 
cover 10% of the U.S. population.13 SEER data include patient 
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demographic information and data on  primary tumor site, 
tumor classification and limited histology, stage at diagnosis, 
first course of cancer treatment, and follow-up for vital status 
from 1973 to 2007. The cancer patient data are collected from 
health providers in hospitals, clinics, pathology labs, and 
physician offices as well as from autopsy reports and death 
certificates.
Cancer Incidence Data
We analyzed data on lung cancer incidence from 1998 
to 2007. Follow-up data until 2007 was acquired. Types of 
lung cancer were identified by international classification of 
diseases for morphology codes.14
Statistical Methods
The methods used to analyze and interpret cancer 
incidence data are the age-adjusted incidence rate and the 
observed-:expected ratio of cancer cases. In the data set under 
study, patients previously diagnosed with stage I lung cancer 
are followed to compare their subsequent cancer diagnoses 
with the number of cancers that would be expected based on 
incidence rates for the general population with no prior cancer 
diagnoses. To control for demographic differences between 
populations, these ratios are adjusted. The standardized inci-
dence ratio (SIR) is the observed number of cases (O) divided 
by the expected number (E) of cases (O/E). In rare malignan-
cies, a high SIR may reflect a higher relative incidence of can-
cer but would not quantify true cancer burden, so absolute 
excess risk (AER) was also used. The AER was calculated for 
10,000 person years at risk by (O−E/person years) × 10,000.
Using SEER STAT statistical software, age-adjusted 
incidence rates were calculated per 100,000 persons using 
U.S. Census 2000 population as the standard for the time 
period 1988–2007.13 Confidence intervals (CI) were calcu-
lated using the Tiwari model for 95% CI.
We used multiple outcome analysis to calculate the SIR 
of secondary malignancies in the survivors of stage I lung 
cancer diagnosed in the period 1988–2003. This time period 
was selected for SIR as to allow at least 4 years of follow-up 
from the time of initial diagnosis. SEER STAT software was 
used to calculate the SIR and AER, and adjusted for age, race, 
site, and calendar year for the corresponding SEER popula-
tion with respect to appropriate person years at risk. We cal-
culated the trend over time of SIR of each second primary 
malignancy since the patient’s initial diagnosis of lung cancer.
RESULTS
From 1988 to 2007 there were a total of 317,528 cases 
of new lung cancers; 45,178 of these cases were stage I. As 
expected, the majority of stage I lung cancers were non–small-
cell carcinoma (43,715 cases). Age-adjusted incidence rates 
of all lung cancers are shown in Table 1. Although the inci-
dence rate of all lung cancers is showing a downward trend, 
the incidence rate of stage I lung cancer increased by 40% 
from 1988 to 2007.
There were 181,159 patient years of follow-up for newly 
diagnosed stage I lung cancer between 1988 and 2003. The 
number of patient years at risk for subsequent malignancy for 
each time period selected since diagnosis is shown in Table 2. 
The incidence data and the O/E ratio for second lung cancer 
and laryngeal cancer (Table 2) is highest in the first year after 
diagnosis and continues to be significantly high 10 years after 
initial diagnosis. The risk for second oral cavity and pharyngeal 
cancer is highest in the first year and decreases over time. At 
10 years, that risk is similar to that of the general population.
 In gastrointestinal malignancies, the relative risk 
of anal (O/E = 1.28; CI: 0.62–2.36; N = 10), hepatobiliary 
(O/E = 1.14; CI: 0.89–1.44; N = 69), and pancreatic (O/E = 1.10; 
CI: 0.9–1.34; N = 104) cancer is the same as that of the 
general population. The cumulative relative risk for colon 
(O/E = 1.33; CI: 1.22–1.44; N = 568), esophagus (O/E = 2.29; 
CI: 1.85–2.89; N = 91), and stomach (O/E = 1.43 CI: 1.15–1.75; 
N = 94) cancers is higher than that of the rest of the popula-
tion. This increased risk is only statistically significant in the 
first 3 to 5 years after initial diagnosis (see Table 3).
In the genitourinary system, there is increased relative 
risk of renal cancer only in the first year after initial lung can-
cer diagnosis (O/E = 5.21; CI: 4.11–6.51; N = 77). In blad-
der cancer (Table 4), the relative risk is high (O/E = 1.83; CI: 
1.65–2.03; N = 363) and remains elevated even at 10 years. In 
female survivors of stage I lung cancers, no increased risk was 
found for malignancies of breast (O/E = 1.07; CI: 0.96–1.18; 
N = 393), ovaries (O/E = 1.1; CI: 0.8–1.6; N = 46), or cervix 
(O/E = 0.69; CI: 0.30–1.35, N = 8). In males survivors, no 
increased risk was found for malignancies of prostate (O/E = 1.02; 
CI: 0.95–1.09; N = 766) or testis (O/E = 1.35; CI: 0.16–4.87, 
N = 2). The cumulative risk of leukemia is not statistically 
increased in this population (O/E = 1.15; CI: 0.94–1.39; N = 105).
TABLE 1. Age-Adjusted Incidence Rates of All Lung Cancer 
and Stage I Lung Cancer per 100,000 Persons Showing 
an Increasing Incidence of Stage I in Contrast to All Lung 
Cancers
Year of Diagnosis Stage I Lung Cancer All Lung Cancer
1988 8 (7.6–8.4) 68 (66.9–69.2)
1989 8 (7.6–8.4) 67.5 (66.4–68.7)
1990 8.5 (8.1–8.9) 68.1 (67–69.2)
1991 8.3 (8–8.7) 69.2 (68.1–70.3)
1992 8.8 (8.4–9.2) 69.4 (68.3–70.5)
1993 8.6 (8.3–9) 67.8 (66.7–68.8)
1994 8.8 (8.4–9.2) 67.1 (66.1–68.2)
1995 9 (8.6–9.4) 66.8 (65.8–67.9)
1996 9.2 (8.8–9.6) 66.4 (65.4–67.5)
1997 9.2 (8.8–9.5) 66.6 (65.5–67.6)
1998 8.8 (8.5–9.2) 67.5 (66.5–68.5)
1999 9.2 (8.8–9.6) 65.8 (64.8–66.8)
2000 8.9 (8.5–9.3) 64.1 (63.1–65.1)
2001 9.2 (8.8–9.6) 64 (63–64.9)
2002 9.4 (9–9.8) 63.7 (62.7–64.7)
2003 9.2 (8.9–9.6) 64.2 (63.3–65.2)
2004 10.1 (9.7–10.5) 61.6 (60.7–62.6)
2005 10.9 (10.5–11.3) 62 (61.1–63)
2006 11.3 (10.9–11.7) 60.9 (60–61.8)
2007 11.2 (10.8–11.7) 59.3 (58.4–60.3)
95% confidence intervals are shown in parentheses.
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DISCUSSION
Analysis of data from the SEER population database 
showed an increasing incidence of stage I lung cancer despite 
a decrease in all stages of lung cancers. There could be many 
reasons for this increase, but we believe that it is because of 
early detection by increased availability and use of CT in clin-
ical practice.1 The fact that the incidence of smoking and all 
lung cancer is decreasing supports the above hypothesis that 
increased imaging is the cause of increased identification of 
stage I lung cancer. Widespread adoption of screening pro-
tocols for lung cancer could lead to a further increase in the 
incidence of stage I lung cancers and survivors.
Individuals with a personal history of lung cancer are at 
risk for other cancers because of the genetic and environmental 
factors such as smoking that contributed to the first cancer 
increase the risk for specific second cancers. In this article we 
showed an increased incidence of second lung, head and neck, 
esophagus, stomach, renal, and bladder cancers in survivors 
of stage I lung cancer. For some of these second cancers, 
such as lung, larynx, and bladder cancer, the increased risk 
persists even after 10 years from the initial diagnosis. In the 
case of other malignancies, such as pharyngeal, esophagus, 
stomach, colorectal, and renal cancers, the increased risk is 
seen only in the first few years and gradually decreases over 
time to that of the general population. There could be many 
reasons for this pattern. Risk modification, such as smoking 
cessation or occupational change since the initial diagnosis, 
may lead to a decreased incidence over time. Because of 
TABLE 2.  Observed/Expected Ratio of Second Lung and Head and Neck Cancers Since Diagnosis of Stage I Lung Cancer
Time 
Period Second Lung Cancer Oral Cavity and Pharynx Larynx
Months O/E Observed
Excess 
Risk O/E Observed
Excess 
Risk O/E Observed
Excess 
risk PYR
0–11 6.78 (6.29–7.31) 695 178.74 3.32 (2.44–4.41) 47 9.91 9.78 (7.51–12.51) 63 17.06 33,151
12–23 3.19 (2.81–3.61) 251 66.86 2.15 (1.37–3.23) 23 4.78 4.19 (2.56–6.48) 20 5.91 25,768
24–35  3.7 (3.25–4.2) 240 82.43 3.13 (2.06–4.55) 27 8.64  3.7 (2.02–6.2) 14 4.81 21,248
36–47 4.41 (3.87–4.99) 246 104.08 2.19 (1.25–3.56) 16 4.76  3.5 (1.75–6.27) 11 4.3 18,271
48–59 4.16 (3.6–4.77) 201 97.42  3.7 (2.34–5.55) 23 10.71 3.04 (1.31–5.98) 8 3.42 15,668
60–71 4.56 (3.92–5.26) 185 110.73 2.91 (1.63–4.8) 15 7.55 2.32 (0.75–5.41) 5 2.18 13,040
72–83 4.96 (4.25–5.77) 170 124.57 2.56 (1.28–4.58) 11 6.15 2.83 (0.92–6.6) 5 2.97 10,897
84–95 4.53 (3.78–5.37) 131 111.97 3.34 (1.73–5.84) 12 9.23 2.73 (0.74–7) 4 2.78 9,114
96–107 4.57 (3.75–5.51) 110 114.23 1.69 (0.55–3.95) 5 2.72 1.67 (0.2–6.05) 2 1.07 7,521
108–119 5.14 (4.2–6.24) 103 134.06 1.64 (0.45–4.2) 4 2.52  4.1 (1.12–10.49) 4 4.88 6,189
120+ 4.12 (3.65–4.64) 276 103.04 1.26 (0.6–2.31) 10 1.01 3.55 (1.77–6.34) 11 3.89 20,287
Total 4.62 (4.44–4.8) 2,608 112.77 2.63 (2.27–3.03) 193 6.6 4.68 (3.95–5.5) 147 6.38 181,158
All time periods are in months from initial diagnosis of stage I lung cancer. Values shown in parentheses are confidence intervals with 95% confidence. Observed is the actual 
number of cases diagnosed, Excess risk is per 10,000 person years, and PYR is patient years at risk for that time period.
O/E, observed/expected ratio; PYR, patient years at risk.
TABLE 3.  Observed/Expected Ratio of Second Gastrointestinal Cancers Since Diagnosis
Time 
Period Esophageal Cancer Stomach Cancer Colorectal Cancer
Months O/E Observed
Excess 
Risk O/E Observed
Excess 
Risk O/E Observed
Excess 
Risk
0–11 2.36 (1.38–3.78) 17 2.96 1.70 (1.05–2.59) 21 2.6 1.41 (1.16–1.7) 111 9.79
12–23    2 (1–3.57) 11 2.13 1.72 (0.99–2.8) 16 2.61 1.61 (1.3–1.97) 96 14.12
24–35 1.99 (0.91–3.77) 9 2.1 1.86 (1.02–3.12) 14 3.05 1.33 (1.03–1.7) 65 7.63
36–47 2.57 (1.23–4.73) 10 3.35 1.25 (0.54–2.46) 8 0.87 1.24 (0.93-1.63) 52 5.53
48–59 2.38 (1.03–4.69) 8 2.96  1.8 (0.87–3.32) 10 2.85  1.1 (0.79–1.5) 40 2.34
60–71 3.19 (1.46–6.05) 9 4.73 1.29 (0.47–2.81) 6 1.04 1.40 (1.02–1.89) 43 9.48
72–83 2.51 (0.92–5.46) 6 3.31 0.00 (0–0.94) 0 −3.61 1.08 (0.72–1.56) 28 1.86
84–95 1.97 (0.54–5.05) 4 2.17  0.9 (0.19–2.64) 3 −0.36 1.36 (0.92–1.95) 30 8.77
96–107 2.96 (0.96–6.91) 5 4.4 0.36 (0.01–2.01) 1 −2.36 1.31 (0.84–1.95) 24 7.52
108–119 1.41 (0.17–5.1) 2 0.94 1.72 (0.47–4.4) 4 2.7 1.44 (0.9–2.18) 22 10.87
120+ 2.08 (1–3.82) 10 2.56 1.43 (0.71–2.56) 11 1.63 1.13 (0.86–1.47) 57 3.33
Total 2.29 (1.85–2.82) 91 2.83 1.43 (1.15–1.75) 94 1.55 1.33 (1.22–1.44) 568 7.75
All time periods are in months from initial diagnosis of stage I lung cancer. Values shown in parentheses are 95% confidence intervals. Patient years at risk are shown in Table 2. 
Excess risk is per 10,000 person years. Observed is the actual number of cases observed.
O/E, observed/expected ratio.
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intense medical scrutiny and increased imaging, there may be 
increased detection of asymptomatic cancers right after initial 
diagnosis. In addition, patients with the highest exposure to 
carcinogens develop second malignancies in the first few 
years after an initial malignancy diagnosis and generally have 
poorer outcomes. Thus, long-term survivors are typically 
those lower-risk patients. We did not find an increased risk of 
pancreatic cancer in survivors of stage I lung cancer as one 
would expect because smoking is a risk factor for both. One 
of the explanations might be that the incidence of pancreatic 
cancer is very low and the increased risk might be small, so 
we might need a bigger cohort to identify the increased risk.
Knowledge of the type of second malignancies and 
the period of risk could help physicians design care plans for 
survivors of stage I lung cancer. For example, the increased 
risk of a second lung cancer persists for more than 10 years 
from the initial diagnosis. Close surveillance and long-term 
follow-up is prudent. There were studies evaluating screening 
in lung cancer survivors for lung cancer recurrence or second 
primary lung cancer with various combinations of clinical, 
laboratory, and radiological studies at different frequency 
with mixed results.15–17 In fact, the recommendations from 
different national societies differ in their surveillance 
recommendations. The American Society of Clinical Oncology 
recommends periodic reviews of patient history and physical 
examinations,18 whereas the National Comprehensive Cancer 
Network guidelines stipulate adding CT-scan screening 
every 6 to 12 months for the first 2 years then annually as 
a category-2B recommendation.19 The European Society of 
Medical Oncology recommends CT scans every 6 months for 
the first 2 years followed by coordination by a multidisciplinary 
team every year thereafter.20 Additional research will identify 
an ideal screening interval.
None of the societies provide a comprehensive survivor-
ship plan addressing the risk of all second malignancies in 
long-term survivors. Most of these patients do not require che-
motherapy and usually follow-up only for the initial few years 
with their pulmonologists and thoracic surgeons. The data pre-
sented assert the need for continued long-term follow-up and 
also helps the clinician to develop a comprehensive survivor-
ship plan. For malignancies that do not have validated screen-
ing techniques, regular physical examinations and symptom/
sign-based approach to workup should help in early detection 
of second malignancies. In rare malignancies such as leuke-
mia, even though there is increased relative risk, the absolute 
risk is low and might not be clinically significant.
There are a few limitations to our analysis, as the SEER 
database may not be a true representation of the U.S. popu-
lation sample. The data set is lacking in certain variables 
such as smoking status, chemotherapy use, radiation therapy 
administered, number of lymph nodes evaluated, or pattern of 
recurrence; this limits the evaluation of these factors on the 
incidence of second cancers. In survivors of lung cancer who 
develop a second lung malignancy, it is difficult to differenti-
ate a recurrent versus a second primary lung tumor, especially 
because the majority of the relapses are close to the initial 
diagnosis. Detailed information on the histological subtype 
of lung cancer that may have made the differentiation easier 
was not available. The second tumor could be a recurrence of 
the primary tumor that was missed during the initial treatment 
(synchronous lesion) or a true second primary (metachronus 
lesion) that has developed in the interval period. This diffi-
culty in differentiation makes staging of the second tumor a 
challenge. Nevertheless, the SEER database provides effec-
tive assessment of the risk of second cancers in long-term sur-
vivors as many years of follow-up data are available.
Clinical trials of novel surveillance strategies and risk-
modification programs addressing all the aspects of care of 
survivors of early stage lung cancer need to be designed and 
validated in prospective, randomized trials. As screening strat-
egies improve, our data may become useful in developing sur-
vivorship plans in the future.
TABLE 4.  Observed/Expected Ratio of Second Renal and Bladder Cancers Since Diagnosis
Time Period Renal Cancer Urinary Bladder Cancer
Months O/E Observed Excess Risk O/E Observed Excess Risk
0–11 5.21 (4.11–6.51) 77 18.77 1.91 (1.48–2.43) 66 9.49
12–23 1.29 (0.72–2.13) 15 1.32 1.81 (1.33–2.4) 48 8.33
24–35 1.43 (0.78–2.4) 14 1.99 2.00 (1.45–2.68) 44 10.34
36–47 1.75 (0.98–2.89) 15 3.53 1.94 (1.36–2.67) 37 9.8
48–59 0.53 (0.15–1.37) 4 −2.23 1.79 (1.21–2.56) 30 8.45
60–71 0.63 (0.17–1.62) 4 −1.79 1.62 (1.03–2.43) 23 6.74
72–83 0.56 (0.11–1.63) 3 −2.18 2.14 (1.39–3.13) 26 12.68
84–95 0.44 (0.05–1.58) 2 −2.83 1.73 (1.02–2.73) 18 8.3
96–107  1.3 (0.42–3.04) 5 1.55 1.71 (0.96–2.82) 15 8.29
108–119 1.24 (0.34–3.18) 4 1.26 0.94 (0.38–1.94) 7 -0.68
120+ 1.07 (0.55–1.87) 12 0.4 1.88 (1.39–2.48) 49 11.28
Total 1.79 (1.52–2.09) 155 3.77 1.83 (1.65–2.03 363 9.1
All time periods are in months from initial diagnosis of stage I lung cancer. Values shown in parentheses are 95% confidence intervals. Patient years at risk are shown in Table 2. 
Excess risk is per 10,000 person years. Observed is the actual number of cases observed. 
O/E, observed/expected ratio.
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